Kiadis and Biofrontera Merge to Form New Company

The new company will be called Aliga Pharmaceuticals AG and its headquarters will be in Leverkusen.

Aliga Pharmaceuticals will serve as a holding company with wholly owned subsidiaries in Leverkusen and Leiden. The new company combines strong drug discovery and development programs focused on pain and central nervous system diseases with a proprietary technology basis, thereby providing innovative drug candidates and R&D solutions for the biotech and pharmaceutical industries.

"Because of an ongoing collaboration between Kiadis and Biofrontera on a joint neuropathic pain program, the enormous potential that a merged company could offer became apparent,” said Dr. Gerard Dijkstra, CEO of the new company. "This merger represents an outstanding opportunity to develop a substantial biopharmaceutical business, based upon Biofrontera's and Kiadis' innovative product portfolio and pioneering drug discovery capabilities.” The company notes that it is the first European private biopharmaceutical business resulting from a German/Dutch across-the-border merger.




Related Links:
Kiadis
Biofrontera